Long-term safety study of an inhaled drug for lung scarring
Part of Lungs & breathing clinical trials.
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed a prior Avalyn study for idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) while on the full dose of the study drug (active or placebo).
- If you are a man or a woman who can have children, you must agree to use effective birth control during the study and for 90 days after the last dose.
- You cannot have had a flare-up of asthma or COPD that needed oral or steroid pills in the last 3 months.
- You cannot have had a sudden worsening of your lung scarring (IPF or PPF) in the last 3 months.
- You should not be taking any other experimental drugs (except the Avalyn study drug) within the past 30 days or 5 half-lives of that drug, whichever is shorter.
- You must not have had a severe allergic reaction to pirfenidone or any ingredients in this study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
This study looks at how patients with pulmonary fibrosis (lung scarring) make decisions about stopping or continuing anti-fibrosis medications, especially if they have had side effects. It may help doctors and patients understand the best treatment choices.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
Hear when a new Progressive Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.